Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Investigator and Subject-Blind, Placebo-Controlled, Single-Dose, 3-Period, Incomplete Block Cross-Over Study to Evaluate the Effects of Single Oral Administration of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

To see complete record on, please visit this link

Id: NCT01892189

Organisation Name: Takeda

Overal Status: Completed

Start Date: August 2013

Last Update: January 12, 2017

Lead Sponsor: Takeda

Brief Summary: The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.

  • Ketamine-Induced Brain Activity Changes
  • Psychotic-like Symptoms

Total execution time in seconds: 0.3295681476593